Breaking News

Q Biomed Extends EOA with Washington U

Allows for more extensive evaluation of GDF15 as a novel biomarker for glaucoma and companion diagnostic to MAN-01

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Q BioMed Inc. is extending its option agreement with Washington University in St. Louis, granting the exclusive right to license its technology. Q BioMed will continue to evaluate the feasibility and usability of GDF15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma.  The agreement allows for more extensive evaluation on the feasibility and usability of GDF15 as a novel biomarker...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters